Medicus Pharma
West Conshohocken, Pennsylvania, United States · Biotechnology, Healthcare, Therapeutics
Medicus Pharma Ltd. (NASDAQ:MDCX) is a biotech/life sciences company focused on accelerating the clinical development programs of novel and potentially disruptive therapeutic assets. The Company is currently advancing the clinical development program of its novel Doxorubicin containing Microneedle Array (D-MNA) treatment to non-invasively treat basal cell carcinoma of the skin (BCC). Medicu
Key facts
- Headquarters
- West Conshohocken, Pennsylvania, United States
- Employees
- 16
- Industries
- Biotechnology, Healthcare, Therapeutics
- Status
- Public (MDCX)
- Website
- medicuspharma.com
- Company page
Recent activity at Medicus Pharma
- : SEC 8-K (7.01): On November 4, 2026, Medicus Pharma Ltd. announced a non-binding letter of intent regarding a potential business combination involving its subsidiary Skinject, Inc. and an undisclosed special purpose acquisition company (SPAC). This filing serves as a Regulation FD Disclosure, providing important information to investors about the potential merger and inviting them to review forthcoming documentation that will be submitted to the SEC. The announcement includes implications for shareholder involvement and the anticipated process for obtaining shareholder approval via a proxy statement, with additional details to be disclosed as they become available. The strategic importance of this combination may enhance Medicus's market presence and operational capabilities within the pharmaceutical sector.
- : SEC 8-K (8.01): On October 20, 2026, the Company received a delisting determination letter from Nasdaq due to non-compliance with the Minimum Bid Price Requirement. However, the situation improved as the Company received a Compliance Notice on October 23, 2026, confirming that it had regained compliance by maintaining a closing bid price of $1.00 or greater over the last ten consecutive business days, from October 12 to October 23, 2026. This outcome effectively closed the delisting matter, although future compliance remains uncertain. The Company had previously been informed of its non-compliance on April 21, 2026, with a deadline of October 19, 2026, to regain compliance, which it initially failed to meet before this recent notice.
- : SEC 8-K (8.01):
- : Medicus Pharma partners with Pfizer for SkinJect co-development and licensing.
- : SEC 8-K (1.02): On September 11, 2026, Medicus Pharma Ltd. mutually agreed with YA II PN, LTD. to terminate the Standby Equity Purchase Agreement (SEPA) originally dated February 10, 2025. The SEPA allowed Medicus Pharma to issue and sell up to $15.0 million worth of common shares to Yorkville. At the time of termination, there were no outstanding amounts due under the agreement, effectively concluding any obligations related to the arrangement. This termination streamlines operations and may indicate a strategic pivot for the company moving forward.
- : Medicus Pharma Ltd. Enters Co-Development and License Agreement with Pfizer
- : SEC 8-K (1.01): On September 2, 2026, Medicus Pharma Ltd. entered into a Co-Development and License Agreement with Pfizer Inc. Under this agreement, Pfizer granted Medicus an exclusive, sublicensable, royalty-bearing worldwide license under specific Pfizer patent rights. The agreement also includes a non-exclusive license under additional terms defined. This collaboration is expected to enhance Medicus's development capabilities while leveraging Pfizer's extensive patent portfolio. Key financial terms of the agreement are not disclosed, but the strategic partnership signifies a significant expansion of Medicus's operational scope in the pharmaceutical sector.
- : Medicus Pharma Appoints Dr Faisal Mehmud as Chief Executive Officer
- : Medicus Pharma Appoints Faisal Mehmud as Chief Executive Officer of Antev
- : Medicus Pharma acquires Antev for Teverelix program
Medicus Pharma funding history
| Date | Round | Amount |
|---|---|---|
| Jun 2024 | Venture | $5.2M |
| Oct 2023 | Seed | $11.0M |
Leadership
- Faisal Mehmud, Chief Executive Officer
- Carolyn Bonner, Chief Financial Officer
- William Ashton, Director
- Raza Bokhari, Executive Officer
- Frank Lavelle, Director
- Robert Ciaruffoli, Director
- Larry Kaiser, Director
- Edward J. Brennan, Chief Scientific Officer
Verified email and direct lines for Medicus Pharma’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
Medicus Pharma files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Medicus Pharma in the news
- Medicus Pharma Announces Proposed SkinJect® Business Combination and Concurrent Financing - GlobeNewswire (Nov 04, 2026)
- Medicus Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement - Yahoo Finance (Oct 26, 2026)
- The FDA authorized a planned skin-cancer study for people with a rare inherited condition. - Stock Titan (Oct 08, 2026)
- Medicus Pharma Advances Transformation into a Precision Oncology-Led Biotechnology Company - GlobeNewswire (Sep 08, 2026)
- A prostate cancer plan could reduce enrollment from about 1,500 to about 600 patients if FDA agrees. - Stock Titan (Sep 29, 2026)
- Medicus Pharma to Present at BioFuture and Global Biotechnology Summit - GlobeNewswire (Oct 27, 2026)
- Medicus Pharma to Showcase SkinJect® Registrational - GlobeNewswire (Jun 22, 2026)
Companies similar to Medicus Pharma
- Galectin · Biotechnology, Healthcare, Therapeutics
- Damora Therapeutics, Inc. · Biotechnology, Healthcare, Therapeutics
- Tessera Defense & Homeland Security Inc. · Biotechnology, Healthcare, Therapeutics
- CytoDyn · Biotechnology, Healthcare, Therapeutics
- Cocrystal Pharma, Inc. · Biotechnology, Healthcare, Therapeutics
About Medicus Pharma: questions and answers
What does Medicus Pharma do?
Medicus Pharma Ltd. (NASDAQ:MDCX) is a biotech/life sciences company focused on accelerating the clinical development programs of novel and potentially disruptive therapeutic assets. The Company is currently advancing the clinical development program of its novel Doxorubicin containing Microneedle Array (D-MNA) treatment to non-invasively treat basal cell carcinoma of the skin (BCC). Medicu
Where is Medicus Pharma headquartered?
Medicus Pharma is headquartered in West Conshohocken, Pennsylvania, United States.
How many employees does Medicus Pharma have?
Medicus Pharma has about 16 employees.
Has Medicus Pharma raised funding?
Yes. Fundz has recorded 2 funding events for Medicus Pharma. The most recent, $5.2M, was in Jun 2024.
Who leads Medicus Pharma?
Faisal Mehmud is a Chief Executive Officer at Medicus Pharma.
What is the latest news on Medicus Pharma?
On Nov 04, 2026, SEC 8-K (7.01): On November 4, 2026, Medicus Pharma Ltd. announced a non-binding letter of intent regarding a potential business combination involving its subsidiary Skinject, Inc. and an undisclosed special purpose acquisition company (SPAC). This filing serves as a Regulation FD Disclosure, provid
Is Medicus Pharma a public company?
Yes. Medicus Pharma is publicly traded under the ticker MDCX.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy